Furthermore, our data illustrate that in both the cell lines and the clinical paired before/during treatment samples, the expression of cyclin D1 (a classical RAS‐MAPK‐regulated transcriptional target [26]) was decreased following RAS‐MAPK inhibition, indicating that CD73 upregulation is compensatory in cancer cells during effective RAS‐MAPK kinase pathway inhibition. This evidence concerns the gene CCND1 and cancer.